Delivery Order SPE2DB20D1004-SPE2DB25FNKCV
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded a delivery order valued at $8,624.79 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 mL pens on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used in diabetes and weight management...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $233,777.40 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designations and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used in diabetes and...
- The Defense Logistics Agency awarded a delivery order valued at $19,897.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used...
- The Defense Logistics Agency awarded a delivery order valued at $2,446.62 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on July 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of July 31, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a recently approved diabetes and weight management...
- The Defense Logistics Agency awarded a delivery order valued at $26,657.11 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, non-set-aside firm fixed price delivery order is being performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a diabetes and weight management medication, consistent with AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $2,045.91 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a diabetes and weight management medication, reflecting...
- The Defense Logistics Agency awarded a $1,143.87 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on July 18, 2025, with completion targeted for July 21, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement executed by the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $11,661.52 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 10 mg/0.5 mL pens with an ultimate completion date of August 14, 2025. Zepbound is a tirzepatide injection used for weight management, and this delivery order represents a competitive procurement with no set-aside designation. The award was placed to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNKCVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,669.05 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, issued without a set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a prescription medication used in diabetes and weight management treatment, and this delivery order represents a continuation of pharmaceutical supply services under the contractor's existing federal contract vehicle. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs and other federal healthcare systems worldwide. The company's federal contracting portfolio demonstrates consistent capability in competitively awarded pharmaceutical procurement across multiple therapeutic domains, supporting Defense Health Agency, U.S. Coast Guard, and related government healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 8/14/25 |